IDEAS home Printed from https://ideas.repec.org/a/epw/ejmed0/v5y2023i3id41697.html

Ocrelizumab-induced Psoriasis in A Patient with Relapsing-Remitting Multiple Sclerosis

Author

Listed:
  • Sara Esmaeili

    (University of Cincinnati, USA)

  • Aram Zabeti

    (University of Cincinnati, USA)

Abstract

Background: Ocrelizumab is widely used as a Disease Modifying Drug (DMD) in Multiple sclerosis. The complete side effects are yet not known. Materials and Methods: We describe a 34-year-old female with longstanding relapsing-remitting Multiple Sclerosis for whom Ocrelizumab was started as an escalation therapy. She reported severe itchy and patchy lesions two months after the first full dose of Ocrelizumab. Pathohistological findings revealed the diagnosis of guttate psoriasis. Psoriasis continued to flare against treatment with topical steroids, and UV therapy and progressed to developed arthritis psoriasis. Results: Treatment escalated to an IL-17 antagonist (Secukinumab), with a favorable outcome. Ocrelizumab was discontinued. After one year of follow-up, the patient remained stable from an MS standpoint. Conclusion: This is the third report showing the possible cutaneous side effect of Ocrelizumab.

Suggested Citation

  • Sara Esmaeili & Aram Zabeti, 2023. "Ocrelizumab-induced Psoriasis in A Patient with Relapsing-Remitting Multiple Sclerosis," European Journal of Medical and Health Sciences, European Open Science, vol. 5(3), pages 1-2, April.
    • Handle: RePEc:epw:ejmed0:v:5:y:2023:i:3:id:41697
    DOI: 10.24018/ejmed.2023.5.3.1697
    as

    Download full text from publisher

    File URL: https://eu-opensci.org/index.php/ejmed/article/view/41697
    File Function: Abstract page
    Download Restriction: no
    File URL: https://eu-opensci.org/index.php/ejmed/article/download/41697/9706
    File Function: Full text
    Download Restriction: no
    File URL: https://libkey.io/10.24018/ejmed.2023.5.3.1697?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Keywords

    ;
    ;
    ;
    ;

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:epw:ejmed0:v:5:y:2023:i:3:id:41697. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Support (email available below). General contact details of provider: https://eu-opensci.org/index.php/ejmed .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.